Galapagos NV (NASDAQ:GLPG) is Stonepine Capital Management LLC’s 4th Largest Position

Stonepine Capital Management LLC grew its holdings in shares of Galapagos NV (NASDAQ:GLPG) by 23.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 485,000 shares of the biotechnology company’s stock after purchasing an additional 91,366 shares during the quarter. Galapagos makes up 11.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 4th largest holding. Stonepine Capital Management LLC owned 0.74% of Galapagos worth $12,018,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Creative Planning purchased a new stake in shares of Galapagos during the 2nd quarter worth approximately $456,000. Millennium Management LLC increased its position in Galapagos by 5.3% in the second quarter. Millennium Management LLC now owns 341,639 shares of the biotechnology company’s stock worth $8,466,000 after buying an additional 17,089 shares during the last quarter. DME Capital Management LP raised its stake in shares of Galapagos by 46.9% in the second quarter. DME Capital Management LP now owns 234,828 shares of the biotechnology company’s stock valued at $5,819,000 after buying an additional 75,000 shares during the period. Marshall Wace LLP purchased a new position in shares of Galapagos during the 2nd quarter valued at $315,000. Finally, XTX Topco Ltd purchased a new stake in Galapagos in the 2nd quarter worth about $284,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Wall Street Analyst Weigh In

GLPG has been the subject of several recent research reports. Raymond James cut Galapagos from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd. Leerink Partners initiated coverage on shares of Galapagos in a research note on Monday, September 9th. They issued a “market perform” rating and a $24.00 price target for the company. Finally, Leerink Partnrs raised shares of Galapagos to a “hold” rating in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $31.00.

Galapagos Stock Down 1.7 %

GLPG stock opened at $28.79 on Tuesday. The firm’s fifty day moving average is $27.58 and its 200 day moving average is $28.18. Galapagos NV has a 52 week low of $24.16 and a 52 week high of $42.46.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.